Baseline characteristics of patients aged ≥65 years per the treatment group
| Characteristic . | Auto-HCT n = 72∗ . | CAR-T n = 53∗ . | P value† . |
|---|---|---|---|
| Sex | .024 | ||
| Male | 52 (72%) | 27 (51%) | |
| Female | 20 (28%) | 26 (49%) | |
| Age at infusion, y | 68.4 (66.6, 73.2) | 70.0 (67.8, 74.3) | .096 |
| Karnofsky performance score | .305 | ||
| 90-100 | 29 (40%) | 14 (26%) | |
| <90 | 42 (58%) | 33 (62%) | |
| Missing | 1 (1.4%) | 6 (11%) | |
| Race | .025 | ||
| White | 46 (64%) | 45 (85%) | |
| Black | 11 (15%) | 3 (5.7%) | |
| Asian | 8 (11%) | 2 (3.8%) | |
| Others | 4 (5.6%) | 0 (0%) | |
| Missing | 3 (4.2%) | 3 (5.7%) | |
| Disease stage | .876 | ||
| Early (stage I/II) | 14 (19%) | 9 (17%) | |
| Advanced (stage III/IV) | 45 (62%) | 35 (66%) | |
| Missing | 13 (18%) | 9 (17%) | |
| Extranodal involvement at diagnosis | .697 | ||
| No | 30 (42%) | 20 (38%) | |
| Yes | 31 (43%) | 26 (49%) | |
| Missing | 11 (15%) | 7 (13%) | |
| Largest node before treatment | .017 | ||
| <3 cm | 15 (21%) | 11 (21%) | |
| 3-5 cm | 19 (26%) | 8 (15%) | |
| >5 cm | 13 (18%) | 24 (45%) | |
| Missing | 25 (35%) | 10 (19%) | |
| Prior lines of therapy | <.001 | ||
| 0-2 | 45 (62%) | 14 (26%) | |
| >2 | 24 (33%) | 37 (70%) | |
| Missing | 3 (4.2%) | 2 (3.8%) | |
| Refractory to first-line therapy | .402 | ||
| No | 30 (42%) | 24 (45%) | |
| Yes | 39 (54%) | 21 (40%) | |
| Missing | 3 (4.2%) | 8 (15%) |
| Characteristic . | Auto-HCT n = 72∗ . | CAR-T n = 53∗ . | P value† . |
|---|---|---|---|
| Sex | .024 | ||
| Male | 52 (72%) | 27 (51%) | |
| Female | 20 (28%) | 26 (49%) | |
| Age at infusion, y | 68.4 (66.6, 73.2) | 70.0 (67.8, 74.3) | .096 |
| Karnofsky performance score | .305 | ||
| 90-100 | 29 (40%) | 14 (26%) | |
| <90 | 42 (58%) | 33 (62%) | |
| Missing | 1 (1.4%) | 6 (11%) | |
| Race | .025 | ||
| White | 46 (64%) | 45 (85%) | |
| Black | 11 (15%) | 3 (5.7%) | |
| Asian | 8 (11%) | 2 (3.8%) | |
| Others | 4 (5.6%) | 0 (0%) | |
| Missing | 3 (4.2%) | 3 (5.7%) | |
| Disease stage | .876 | ||
| Early (stage I/II) | 14 (19%) | 9 (17%) | |
| Advanced (stage III/IV) | 45 (62%) | 35 (66%) | |
| Missing | 13 (18%) | 9 (17%) | |
| Extranodal involvement at diagnosis | .697 | ||
| No | 30 (42%) | 20 (38%) | |
| Yes | 31 (43%) | 26 (49%) | |
| Missing | 11 (15%) | 7 (13%) | |
| Largest node before treatment | .017 | ||
| <3 cm | 15 (21%) | 11 (21%) | |
| 3-5 cm | 19 (26%) | 8 (15%) | |
| >5 cm | 13 (18%) | 24 (45%) | |
| Missing | 25 (35%) | 10 (19%) | |
| Prior lines of therapy | <.001 | ||
| 0-2 | 45 (62%) | 14 (26%) | |
| >2 | 24 (33%) | 37 (70%) | |
| Missing | 3 (4.2%) | 2 (3.8%) | |
| Refractory to first-line therapy | .402 | ||
| No | 30 (42%) | 24 (45%) | |
| Yes | 39 (54%) | 21 (40%) | |
| Missing | 3 (4.2%) | 8 (15%) |